MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway

Cellular Immunology

Volumn 306-307, Issue , 2016, Pages 35-40

  Sang, Wei ^a   Sun, Cai ^a   Zhang, Cong ^b   Zhang, Dianzheng ^c   Wang, Ying ^a   Xu, Linyan ^a   Zhang, Zhe ^a   Wei, Xiangyu ^a   Pan, Bin ^a   Yan, Dongmei ^a   Zhu, Feng ^a   Yan, Zhiling ^a   Cao, Jiang ^a   Loughran, Thomas P ^d   Xu, Kailin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Huaibei Mineral General Hospital   (China)

^c PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AKT3; Apoptosis; Bim; CD4+ T cells; miR 150

Indexed keywords

BIM PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; MICRORNA 150; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; V AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3; AKT3 PROTEIN, HUMAN; BCL2L11 PROTEIN, MOUSE; MIRN150 MICRORNA, HUMAN; PROTEIN BCL 2; PROTEIN KINASE B;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; ALLOTRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; GENETICS; GRAFT VS HOST DISEASE; HEK293 CELL LINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY;

APOPTOSIS; BCL-2-LIKE PROTEIN 11; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; GRAFT VS HOST DISEASE; HEK293 CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84977556041     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2016.05.007     Document Type: Article

References (26)

1. + T cells in rheumatoid arthritis. PLoS One, 9(6), 2014, e100690.
2. [2] Lee, J., Shin, E.K., Lee, S.Y., Her, Y.M., Park, M.K., Kwok, S.K., Ju, J.H., Park, K.S., Kim, H.Y., Cho, M.L., Park, S.H., Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology 142:4 (2014), 573–580.
3. [3] Ferrara, J.L., Levine, J.E., Reddy, P., Holler, E., Graft-versus-host disease. Lancet 373:9674 (2009), 1550–1561.
4. [4] Ferrara, J.L., Reddy, P., Pathophysiology of graft-versus-host disease. Semin. Hematol. 43:1 (2006), 3–10.
5. + T cells. Blood 105:5 (2005), 2206–2213.
6. [6] Kim, J., Kim, H.J., Park, K., Kim, J., Choi, H.J., Yagita, H., Nam, S.H., Cho, H.R., Kwon, B., Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood 110:2 (2007), 776–782.
7. [7] Xu, K.L., Zhang, Y., Pan, X.Y., Lu, Q.X., Inhibiting the expression of CD28 costimulatory molecule on human lymphocytes by special siRNA. Chin. Med. J. (Engl.) 118:6 (2005), 480–486.
8. [8] Lopez-Ramirez, M.A., Nicoli, S., Role of miRNAs and epigenetics in neural stem cell fate determination. Epigenetics 9:1 (2014), 90–100.
9. [9] Osella, M., Riba, A., Testori, A., Corà, D., Caselle, M.1., Interplay of microRNA and epigenetic regulation in the human regulatory network. Front. Genet., 5, 2014, 345.
10. [10] Liu, J., Wu, C.P., Lu, B.F., Jiang, J.T., Mechanism of T cell regulation by microRNAs. Cancer Biol. Med. 10:3 (2013), 131–137.
11. [11] Monticelli, S., Ansel, K.M., Xiao, C., Socci, N.D., Krichevsky, A.M., Thai, T.H., Rajewsky, N., Marks, D.S., Sander, C., Rajewsky, K., Rao, A., Kosik, K.S., MicroRNA profiling of the murine hematopoietic system. Genome Biol., 6(8), 2005, R71.
12. [12] Zhou, B., Wang, S., Mayr, C., Bartel, D.P., Lodish, H.F., MiR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc. Natl. Acad. Sci. U.S.A. 104:17 (2007), 7080–7085.
13. [13] Zheng, Q., Zhou, L., Mi, Q.S., MicroRNA miR-150 is involved in Vα14 invariant NKT cell development and function. J. Immunol. 188:5 (2012), 2118–2126.
14. [14] Bezman, N.A., Chakraborty, T., Bender, T., Lanier, L.L., MiR-150 regulates the development of NK and iNKT cells. J. Exp. Med. 208:13 (2011), 2717–2731.
15. [15] Sang, Wei, Zhang, Cong, Zhang, Dianzheng, Wang, Ying, Sun, Cai, Niu, Mingshan, Sun, Xiaoshen, Zhou, Cui, Zeng, Lingyu, Pan, Bin, Chen, Wei, Yan, Dongmei, Zhu, Feng, Wu, Qingyun, Cao, Jiang, Zhao, Kai, Chen, Chong, Li, Zhenyu, Li, Depeng, Loughran, Thomas P. Jr., Xu, Kailin, MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production. Am. J. Hematol. 90:11 (2015), 998–1007.
16. [16] Reynolds, C., Roderick, J.E., LaBelle, J.L., Bird, G., Mathieu, R., Bodaar, K., Colon, D., Pyati, U., Stevenson, K.E., Qi, J., Harris, M., Silverman, L.B., Sallan, S.E., Bradner, J.E., Neuberg, D.S., Look, A.T., Walensky, L.D., Kelliher, M.A., Gutierrez, A., Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia 28:9 (2014), 1819–1827.
17. [17] Yu, Y., Wang, D., Liu, C., Kaosaard, K., Semple, K., Anasetti, C., Yu, X.Z., Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 118:18 (2011), 5011–5020.
18. [18] Hippen, K.L., Riley, J.L., June, C.H., Blazar, B.R., Clinical perspectives for regulatory T cells in transplantation tolerance. Semin. Immunol. 23:6 (2011), 462–468.
19. [19] Serody, J.S., Hill, G.R., The IL-17 differentiation pathway and its role in transplant outcome. Biol. Blood Marrow Transplant. 18:Suppl. 1 (2012), S56–S61.
20. [20] Farh, K.K., Grimson, A., Jan, C., Lewis, B.P., Johnston, W.K., Lim, L.P., Burge, C.B., Bartel, D.P., The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310:5755 (2005), 1817–1821.
21. [21] Landau, D.A., Slack, F.J., MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin. Oncol. 38:6 (2011), 743–751.
22. [22] Shan, J., Feng, L., Luo, L., Wu, W., Li, C., Li, S., Li, Y., MicroRNAs: potential biomarker in organ transplantation. Transpl. Immunol. 24:4 (2011), 210–215.
23. [23] Cheung, M., Testa, J.R., Diverse mechanisms of AKT pathway activation in human malignancy. Curr. Cancer Drug Targets 13:3 (2013), 234–244.
24. [24] Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129:7 (2007), 1261–1274.
25. [25] Shao, Y., Aplin, A.E., Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70:16 (2010), 6670–6681.
26. [26] Paraiso, K.H., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., Munko, A.C., Wood, E., Fedorenko, I.V., Sondak, V.K., Anderson, A.R., Ribas, A., Palma, M.D., Nathanson, K.L., Koomen, J.M., Messina, J.L., Smalley, K.S., PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71:7 (2011), 2750–2760.